Effects of high-dose phytoestrogens on circulating cellular microparticles and coagulation function in postmenopausal women
| Autor: | Hui-Yu Peng, I-Shaw Jan, Ssu-Chun Hsu, Chih Hsing Wu, Shu-Yi Wang, Chao-Wei Liu, Ning-Sing Shaw, Ching-I Chang, Wern-Cherng Cheng, Keh-Sung Tsai, Chi-Ling Chen, Tong-Yuan Tai, Li-Na Lee, Jin-Shan Wu, Shih-Te Tu, Shyi-Chyi Lo |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class medicine.medical_treatment Taiwan Physiology postmenopausal women coagulation factors Placebo Double-Blind Method Cell-Derived Microparticles Internal medicine Coagulation testing Medicine Humans Prospective Studies isoflavones Blood Coagulation microparticles phytoestrogens Medicine(all) lcsh:R5-920 Hematology medicine.diagnostic_test business.industry Hormone replacement therapy (menopause) General Medicine Middle Aged medicine.disease Blood Coagulation Factors Healthy Volunteers Menopause Postmenopause Endocrinology Blood pressure Estrogen Female lcsh:Medicine (General) business Liver function tests Biomarkers |
| Zdroj: | Journal of the Formosan Medical Association, Vol 114, Iss 8, Pp 710-716 (2015) |
| ISSN: | 0929-6646 |
| DOI: | 10.1016/j.jfma.2013.11.001 |
| Popis: | Background/Purpose Estrogen in hormone replacement therapy causes homeostatic changes. However, little is known regarding the safety of high-dose phytoestrogen on coagulation and hematological parameters in healthy postmenopausal women. This study evaluated the effects of high-dose soy isoflavone (300 mg/day) on blood pressure, hematological parameters, and coagulation functions including circulating microparticles in healthy postmenopausal women. Methods The original study is a 2-year prospective, double-blind, placebo-controlled study. In total, 431 postmenopausal women (from 3 medical centers) were randomly assigned to receive either high-dose isoflavone or placebo for 2 years. At baseline, 6 months, 1 year, and 2 years after treatment, blood pressure, body weight, liver function tests, hematological parameters, and lipid profiles were measured. The 1 st year blood specimens of 85 cases of 144 eligible participants (from one of the three centers) were analyzed as D-dimer, von Willebrand factor antigen, factor VII, plasminogen activator inhibitor type 1, and circulating cellular microparticles, including the measurement of monocyte, platelet, and endothelial microparticles. Results In the isoflavone group, after 1 year, the changes in liver function tests, hematological parameters, and coagulation tests were not different from those of the control. Triglyceride levels were significantly lower after 6 months of isoflavone treatment than the placebo group, but the difference did not persist after 1 year. Endothelial microparticles increased steadily in both groups during the 1-year period but the trend was not affected by treatment. Conclusion The results of the present study indicate that high-dose isoflavone treatment (300 mg/day) does not cause hematological abnormalities or activate coagulation factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|